Abstract
PURPOSE : The analysis of new cohesive and adhesive OVDs (Kogevisk and Adgevisk, Solopharm) influence on the intraocular pressure (IOP) level in early postoperative period after phacoemulsification. METHODS : The clinical study was based on an assessment of the clinical and functional state of 60 patients (60 eyes), which were divided into 2 groups depending on ophthalmic viscoelastic device (OVD) used during the operation of phacoemulsification (Softshell technology): in Group I (30 patients, 30 eyes) Adgevisk was introduced for tissue protection, and Kogevisk — to create volume; in Group II (30 patients, 30 eyes), Viscoat was used to protect tissues and Amvisk Plus was used to create volume. During the postoperative period, all patients received standard anti-inflammatory therapy. There were no statistically significant differences in average patient age, operation field, preoperative intraocular pressure (IOP), and preoperative central corneal thickness (CCT) between the two groups. Prior to the surgery and in the postoperative period (after 30 minutes, 2 hours, 1 day, 7 days) the level of IOP was measured, and one day and one week after the surgery we measured CCT values and endothelial cells density (ECD). The duration of the operation and the amount of fluid required during each operation were also assessed. RESULTS : Each patient showed a transient increase in IOP level, reaching its maximum 2 hours after the operation. There was no statistically significant difference in the severity of transient ophthalmic hypertension between the two groups, as well as between CCT and ECD values. There was no significant difference in the time of surgery between the groups. No complications were observed during the intraocular lens implantation in the two groups. CONCLUSION : The investigated OVDs Adgevisk and Kogevisk showed ease of use, safety, and the absence of adverse effects. Post-surgical changes in the IOP level after the use of Adgevisk and Kogevisk were comparable with those after other OVDs use. The reduced cost of the new OVDs presents an additional advantage.
Paper version not known (
Free)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
